>
Akers Biosciences Inc logo

AKR - Akers Biosciences Inc Share Price

57.5p 0.0  0.0%

Last Trade - 28/03/19

Sector
Healthcare
Size
Small Cap
Market Cap £63.6m
Enterprise Value £38.5m
Revenue £n/a
Position in Universe th / 1826
Bullish
Bearish
Unlock AKR Revenue
Momentum
Relative Strength (%)
1m -33.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.12 2.96 3.35 1.67 0.000 0.000 -100.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, MyMDPharmaceuticals Inc revenues was not reported. Net lossbefore extraordinary items increased from $3.4M to $12.2M.Higher net loss reflects Research and Development Expensesincrease from $0K to $8M (expense), Administrative Expenses- Balancing valu increase of 20% to $3.2M (expense),Personnel Costs - Administrative Expense increase of 57% to$1.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AKR Revenue Unlock AKR Revenue

Net Income

AKR Net Income Unlock AKR Revenue

Normalised EPS

AKR Normalised EPS Unlock AKR Revenue

PE Ratio Range

AKR PE Ratio Range Unlock AKR Revenue

Dividend Yield Range

AKR Dividend Yield Range Unlock AKR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AKR EPS Forecasts Unlock AKR Revenue
Profile Summary

MyMD Pharmaceuticals, Inc., formerly Akers Biosciences, Inc., is a clinical stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MyMD-1 is being developed to treat age-related illnesses such as frailty and sarcopenia. MyMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-α, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic derivative of Cannabidiol (CBD) being developed to treat various conditions, including, but not limited to, epilepsy, pain and anxiety or depression.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated March 9, 1989
Public Since July 24, 2008
No. of Shareholders: 755
No. of Employees: 4
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange London Stock Exchange (Dual Listing)
Shares in Issue 37,282,169
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AKR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AKR
Upcoming Events for AKR
Frequently Asked Questions for Akers Biosciences Inc
What is the Akers Biosciences Inc share price?

As of 28/03/19, shares in Akers Biosciences Inc are trading at 57.5p, giving the company a market capitalisation of £63.6m. This share price information is delayed by 15 minutes.

How has the Akers Biosciences Inc share price performed this year?

Shares in Akers Biosciences Inc are currently trading at 57.5p and the price has moved by -88.31% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Akers Biosciences Inc price has moved by -90.6% over the past year.

What are the analyst and broker recommendations for Akers Biosciences Inc?

Of the analysts with advisory recommendations for Akers Biosciences Inc, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Akers Biosciences Inc is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Akers Biosciences Inc next release its financial results?

Akers Biosciences Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Akers Biosciences Inc dividend yield?

Akers Biosciences Inc does not currently pay a dividend.

Does Akers Biosciences Inc pay a dividend?

Akers Biosciences Inc does not currently pay a dividend.

When does Akers Biosciences Inc next pay dividends?

Akers Biosciences Inc does not currently pay a dividend.

How do I buy Akers Biosciences Inc shares?

To buy shares in Akers Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Akers Biosciences Inc?

Shares in Akers Biosciences Inc are currently trading at 57.5p, giving the company a market capitalisation of £63.6m.

Where are Akers Biosciences Inc shares listed? Where are Akers Biosciences Inc shares listed?

Here are the trading details for Akers Biosciences Inc:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: AKR
What kind of share is Akers Biosciences Inc?

We were not able to load our ranking data for Akers Biosciences Inc

Is there a Akers Biosciences Inc share price forecast 2021?

We were not able to load any forecast data for Akers Biosciences Inc.

How can I tell whether the Akers Biosciences Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akers Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been -68%. At the current price of 57.5p, shares in Akers Biosciences Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Akers Biosciences Inc PE Ratio?

We were not able to find PE ratio data for Akers Biosciences Inc.

Who are the key directors of Akers Biosciences Inc?

Akers Biosciences Inc's management team is headed by:

Bill White - IND
Joshua Silverman - CHM
Robert Schroeder - IND
Ian Rhodes - CFO
Chris Chapman - PRE
Adam Kaplin - CSO
Paul Rivard - EVP
Craig Eagle - DRC
Jude Uzonwanne - DRC
Who are the major shareholders of Akers Biosciences Inc?

Here are the top five shareholders of Akers Biosciences Inc based on the size of their shareholding:

Similar to AKR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.